Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
Researchers measured proteins produced by 193 deletions in 136 CRISPR-deleted genes and found residual protein expression in roughly one-third of these cases.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The study is one of several recent efforts to detect bacteria directly with mass spec, which could eliminate the need for culturing and speed turnaround time.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
Gathering last week in Australia, the community continued its years-long push towards increased clinical relevance and integration with other omics disciplines.
The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.
The approach uses miniaturized sample prep and isobaric tagging and can identify up to 2,300 proteins in single cells and analyze around 100 cells per day.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
